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Abstract
Background: MicroRNAs (miRNAs, miRs) are small non-coding RNAs that negatively regulate gene expression at the post-
transcriptional level. MicroRNAs are dysregulated in cancer and may play essential roles in tumorigenesis. Additionally,
miRNAs have been shown to have prognostic and diagnostic value in certain types of cancer. The objective of this study
was to identify dysregulated miRNAs in endometrioid endometrial adenocarcinoma (EEC) and the precursor lesion, complex
atypical hyperplasia (CAH).
Methodology: We compared the expression profiles of 723 human miRNAs from 14 cases of EEC, 10 cases of CAH, and 10
normal proliferative endometria controls using Agilent Human miRNA arrays following RNA extraction from formalin-fixed
paraffin-embedded (FFPE) tissues. The expression of 4 dysregulated miRNAs was validated using real time reverse
transcription-PCR.
Results: Forty-three miRNAs were dysregulated in EEC and CAH compared to normal controls (p,0.05). The entire miR-200
family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC.
Conclusions: This information contributes to the candidate miRNA expression profile that has been generated for EEC and
shows that certain miRNAs are dysregulated in the precursor lesion, CAH. These miRNAs in particular may play important
roles in tumorigenesis. Examination of miRNAs that are consistently dysregulated in various studies of EEC, like the miR-200
family, will aid in the understanding of the role that miRNAs play in tumorigenesis in this tumour type.
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Introduction
Endometrial carcinoma is the most common gynecologic
malignancy in Canada with an estimated 4700 new cases and
750 resultant deaths in 2011 [1]. Approximately 70 to 80 percent
of newly diagnosed cases of endometrial cancer are endometrioid
endometrial adenocarcinomas (EEC) which occur at a median age
of 60. They are associated with chronic exposure to unopposed
estrogen and are often preceded by complex atypical hyperplasia
(CAH).
Recently, molecular studies have identified microsatellite
instability and mutations in PTEN, K-ras, PIK3CA, and beta-
catenin genes in cases of EEC [2,3]. The identification of these
molecular derangements can aid our understanding of EEC and
can also lead to the discovery of novel targets for detection,
prognosis, and prediction. Although these genetic alterations have
been described, they are not universally present in all cases of EEC
suggesting that other mutations or epigenetic alterations may also
be important.
MicroRNAs (miRNAs) are a class of small RNAs (20–25
nucleotides in length) that are important regulatory molecules in
plants, animals and viruses [4,5]. Since their discovery [6–8], it
has become clear that miRNAs regulate several key cellular
processes including developmental timing [9], stem cell division
[10–14] and apoptosis [15–17]. MicroRNAs likely influence these
processes by post-transcriptional negative regulation of gene
expression through binding to messenger RNA (mRNA) targets,
causing mRNA cleavage, translational repression, or mRNA
decay [5]. More than 50 percent of human miRNA genes are
located at fragile sites or in regions known to be dysregulated by
loss, amplification or breakage in cancer [18]. Using molecular
techniques, dysregulated miRNAs have been identified in many
human cancers including those of the lung, breast, testes,
prostate, ovary, liver, pancreas, brain, colon, and in hematolog-
ical malignancies like leukemia [19]. In some cases, the
dysregulated miRNAs confer a ‘‘tumour signature’’ that can be
exploited for diagnostic purposes. It has been proposed that
overexpressed miRNAs may function as oncogenes while those
that are underexpressed behave as tumour suppressor genes [19].
MicroRNA expression profiles are becoming useful tools in
cancer diagnostics, screening and prognosis, and may play a
future role in cancer therapeutics.
In this study, we used the Agilent microarray platform to screen
for differentially expressed miRNAs in EEC as well as in the
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miRNAs using real-time reverse transcription-PCR (real time RT-
PCR). The aims of this study were to determine the panel of
dysregulated miRNAs in EEC for further use in diagnostics and to
investigate the potential role of miRNAs in this tumour.
Methods
Ethics Statement
This study was approved by the Queen’s University Research
Ethics Board and all participants signed a consent form prior to
their surgical procedure.
Samples
For discovery, formalin-fixed paraffin-embedded (FFPE) sam-
ples of CAH (n=10), EEC (n=14) and normal proliferative
endometrium (n=10) from hysterectomy specimens were identi-
fied in the Pathology Department at Kingston General Hospital
(Ontario, Canada). For the biological validation studies, additional
FFPE cases of CAH (n=4) and EEC (n=5) from endometrial
biopsies or hysterectomy specimens were identified. Inclusion
criteria for all cases included: (i) unambiguous histology and
absence of mixed tumour types; (ii) sufficient viable tissue available
for RNA extraction; (iii) absence of any treatment prior to surgery;
and (iv) age of tissue block less than 7 years. The histology was
Table 1. Clinicopathologic characteristics of the cases used in the microarray.
Case Number Age Reason for Hysterectomy FIGO Grade FIGO Stage
Normal Controls
99 38 Dysmenorrhia and menorrhagia
57 37 Leiomyomata
55 49 Uterine prolapse
71 44 Ovarian cyst
81 49 Leiomyomata
80 40 Leiomyomata
76 47 Uterine prolapse
77 52 Uterine prolapse and menorrhagia
64 28 Dysmenorrhea
74 48 Ovarian cyst
Atypical Hyperplasia Cases
61 60
98 59
65 62
97 61
94 47
62 63
90 56
73 59
63 36
79 59
Endometrial Carcinoma Cases
39 64 1 IA
16 64 1 IA
33 76 1 IA
37 68 1 IA
38 71 2 IB
10 56 2 IB
26 59 2 IA
29 47 2 IA
25 33 2 IA
48 49 2 IB
21 75 2 II
40 66 3 IB
34 67 3 1A
49 55 3 1A
FIGO=Federation Internationale de Gynecologie d’Obstetrique.
doi:10.1371/journal.pone.0022828.t001
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block with sufficient tissue for analysis were marked. Two to 5
cores (0.6 mm) of tissue were obtained from the FFPE blocks for
RNA extraction.
RNA Extraction
Total RNA was extracted from the FFPE tissue cores using the
Ambion RecoverAll Total Nucleic Acid Isolation Kit for FFPE
tissues (Applied Biosystems/Ambion, Austin TX, USA) according
to the manufacturer’s instructions with a modified digestion time
(5 hours). The quantity and quality of the total RNA was verified
with the NanoDrop spectrophotometer (Thermo Fisher Scientific
Incorporated, Wilmington DE, USA) according to the manufac-
turer’s instructions.
Labeling and Microarray
One hundred nanograms of total RNA was labeled using the
Agilent miRNA Complete Labeling and Hybridization Kit
(Agilent Technologies Incorporated, Santa Clara CA, USA)
according to the manufacturer’s instructions. The labeled RNA
was hybridized to the Agilent Human miRNA Microarray (V2,
Agilent) which contains probes for 723 mature human miRNAs.
Arrays were scanned using an Agilent scanner and feature
extracted using Agilent Feature Extraction Software, version
10.5.1.1.
Analysis
Expression data were initially normalized to the 75
th percentile
and then averaged among the groups using GeneSpring GX
(Agilent) software. The Kruskall-Wallis test was used for
comparisons among the groups and the Benjamini-Hochberg
correction was applied to adjust for multiple comparisons.
Unsupervised hierarchical clustering was performed using Gene-
spring GX software.
Target Prediction
MicroCosm Targets version 5 [20] was used to examine the
gene targets of our miRNAs of interest.
Real-time RT-PCR
To validate key microarray results, quantitative reverse
transcription (RT) was performed using the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems (ABI)), Foster City
CA, USA) with ABI miRNA specific primers and primer kits on an
Eppendorf Realplex Thermal Cycler (Mississauga ON, Canada).
Specific kits used were as follows: miR-542-5p: ABI#002240;
miR-200a: ABI#000502; miR-429: ABI#001024; miR-503:
ABI#001048. Relative expression levels were calculated using
the comparative Ct (2
2DDCt) method with U6 small nuclear RNA
as the endogenous control. Samples were analyzed in triplicate.
Technical validations were carried out using a subset of the
original samples that were used in the discovery phase of the study
(4 samples each of EEC and CAH and 3 normal controls).
Biological validation was performed using additional FFPE cases
of CAH (n=4) and EEC (n=5).
Table 2. Differentially expressed microRNAs (p,0.05)
showing decreased expression in EEC (fold change).
MicroRNA CAH vs Control EEC vs CAH EEC vs Control
miR-100 21.6 23.4 25.5
miR-10b* 2.2 25.0 22.3
miR-127-3p 22.4 21.8 24.5
miR-152 22.1 22.2 24.6
miR-199b-3p 22.1 22.4 25.0
miR-199b-5p 22.3 23.2 27.4
miR-23a* 21.8 22.2 24.1
miR-370 1.4 24.4 23.2
miR-376a 22.4 22.8 26.6
miR-376c 22.1 24.5 29.6
miR-381 22.1 22.0 24.2
miR-410 22.4 21.7 24.2
miR-424 24.1 22.6 210.7
miR-424* 21.2 24.0 24.9
miR-431 2.2 24.3 21.9
miR-432 21.9 22.4 24.6
miR-503 28.6 23.2 227.3
miR-542-3p 23.2 22.1 26.9
miR-542-5p 22.0 23.1 26.1
miR-596 2.2 24.4 22.0
miR-610 1.9 25.1 22.7
miR-630 2.0 25.2 22.6
miR-632 1.9 26.6 23.4
miR-760 1.2 25.4 24.5
Down-regulated miRNAs are designated with a negative fold change.
MicroRNAs which have similar expression changes in other studies of EEC are
italicized.
doi:10.1371/journal.pone.0022828.t002
Table 3. Differentially expressed microRNAs (p,0.05)
showing increased expression in EEC (fold change).
MicroRNA CAH vs Control EEC vs CAH EEC vs Control
miR-141 1.2 3.9 4.8
miR-146a 1.0 6.9 7.1
miR-18a 22.9 4.4 1.5
miR-200a 1.2 4.9 6.1
miR-200b 1.1 5.9 6.6
miR-200b* 1.6 2.9 4.6
miR-200c 21.0 4.3 4.2
miR-203 21.1 6.2 5.4
miR-205 6.6 2.3 15.3
miR-210 1.2 5.7 6.7
miR-421 21.5 4.0 2.8
miR-429 1.1 6.2 6.8
miR-516a-5p 4.4 23.6 1.2
miR-605 21.7 4.2 2.4
miR-614 4.5 22.8 1.6
miR-9 1.3 4.0 5.1
miR-9* 2.3 3.5 8.2
miR-936 4.2 23.0 1.4
miR-96 21.1 4.3 3.8
Down-regulated miRNAs are designated with a negative fold change.
MicroRNAs which have similar expression changes in other studies of EEC are
italicized and the miR-200 family miRNAs are bolded.
doi:10.1371/journal.pone.0022828.t003
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Samples
Clinicopathologic information on the cases used for the
microarray is included in Table 1. The carcinoma cases included
predominantly stage I disease, with one case classified as stage II.
Microarray Expression Profiles
As recommended by Shi et al [21], differentially expressed
miRNAs were chosen based on a high fold change (at least 4-fold
change in at least one group comparison) and a non-stringent p
cutoff (p,0.05). This resulted in the identification of 43 miRNAs
that differ significantly between EEC, CAH and normal controls
(Tables 2 and 3).
Hierarchical Clustering
Figure 1 illustrates the results of the unsupervised hierarchical
clustering based on the expression of the significantly differentially
expressed miRNAs listed in Tables 2 and 3.
Real-time RT-PCR
Two separate validation steps were performed using real-time
RT-PCR. The first step was a technical validation using samples
from the original set characterized on the microarray. For the
biological validation step, RNA was isolated from a new set of
FFPE tissues as described above to increase the likelihood that the
observed differences in miRNA expression profiles represent
biologically significant changes.
Figure 1. Unsupervised hierarchical clustering of normal endometrium (brown), atypical hyperplasia (red) and EEC (blue). Samples
are in columns and miRNAs are in rows.
doi:10.1371/journal.pone.0022828.g001
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was based on their differential expression among the groups as well
as their putative biological significance: miR-542-5p is predicted to
target estrogen receptor alpha mRNA; miR-200a and miR-429
are both members of the miR-200 family; and miR-503 is the most
down-regulated miRNA in both types of carcinoma and the
precursor lesion. Figure 2 depicts the results of the validation real-
time RT-PCR. For all four of the miRNAs examined, changes in
the expression pattern observed in the technical and biological
validation sets were consistent with the changes observed by
microarray.
Discussion
The identification of molecular species that can differentiate
between tumour and normal tissue, or between precursor and
tumour tissues, is widely considered to be useful for a number of
reasons. First, the identification of consistently dysregulated
patterns of expression can lead to clues about the biological
processes that lead to the development or progression of cancer.
Second, the identification of these markers can provide rapid
methods for diagnostic or prognostic tests. And thirdly,
continued understanding of the pathways that are targeted
during tumour development can ultimately lead to the
identification of novel and specific druggable targets, ultimately
affecting patient outcomes.
In the case of endometrial carcinoma, we set out to identify
miRNA species that might differentiate between EEC and CAH,
and differentiate both from normal controls. We argued that
examination of the dysregulated miRNAs might reveal important
steps in both early endometrial carcinogenesis and progression to
invasive carcinoma. Additionally, a subset of the miRNAs show
discordant expression in CAH and EEC compared to controls (ie:
increased expression in CAH and decreased expression in EEC
compared to controls; Table 2). There is the potential to use such
miRNAs to distinguish between CAH and EEC which would be
beneficial, especially on small biopsies where more complex testing
might not be possible.
We identified 43 microRNAs that are dysregulated in EEC and
CAH compared to normal controls. Clustering analysis shows that
these 43 miRNAs can differentiate EEC from both CAH and
normal controls. Furthermore, the dysregulated miRNAs show
intermediate expression level changes in the precursor lesion,
CAH.
Figure 2. Quantitative RT-PCR results. Validation RT-PCR was performed using formalin-fixed paraffin embedded tissues from the original
sample set as well as a new sample set using primers for miR-200a (A), miR-429 (B), miR-503 (C), and miR-542-5p (D). Error bars represent standard
deviation.
doi:10.1371/journal.pone.0022828.g002
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published reports [22–26]; Table 4. The most striking similarity is
the up-regulation of the miR-200 family (miR-141, 200a, 200b,
200c, 429) in EEC relative to normal controls. This up-regulation
among different studies is observed consistently despite the use of
different patient populations, different tissue types (fresh vs
formalin-fixed), different investigative platforms (RT-PCR vs
microarray) and different control tissues (atrophic vs proliferative
endometrium vs mixed proliferative/secretory vs normal adja-
cent). In our study, this up-regulation is additionally observed in
the precursor lesion.
The miR-200 family consists of five members localized on two
genomic clusters (miR-200a/b, miR-429 on chromosome 1, and
miR-200c, miR-141 on chromosome 12) [27]. The miR-200
family has been implicated in the epithelial-to-mesenchymal
transition (EMT) that occurs as a part of tumour invasion and
metastasis [28–30]. Briefly, these miRNAs have been shown to
negatively regulate two transcription factors, ZEB1 and ZEB2,
which in turn negatively regulate E-cadherin. When ZEB1 and
ZEB2 are overexpressed, levels of E-cadherin go down and cells
adopt a mesenchymal phenotype that is better able to invade
tissues and metastasize. Conversely, if ZEB1 and ZEB2 levels are
low, as would be expected with high miR-205 and miR-200 family
members, E-cadherin levels increase and an epithelial phenotype
should be maintained.
Studies have shown an association with low miR-200 family
levels and an aggressive tumour phenotype [31,32] consistent with
the regulation of the EMT switch as described. However, there are
some tumour types in which an up-regulation of the miR-200
family has been observed. These include melanoma [33,34],
ovarian carcinoma [35] and colorectal carcinoma [36]. Cochrane
et al [37] have shown that miR-200c levels are associated with a
less aggressive tumour phenotype in ovarian cancer, breast cancer
and EEC cancer cell lines. Recently, Castilla et al [38] have
demonstrated differential miRNA expression levels between the
epithelial and mesenchymal elements in uterine carcinosarcoma,
with up-regulation of the miR-200 family in the epithelial part.
Insights into the up-regulation of the miR-200 family in certain
tumour types, including endometrial carcinoma, may be gained by
examining the role of steroid receptors in the regulation of
miRNAs. A recent review by Cochrane et al [39] describes the
regulation of the miR-200 family by estrogen receptor-a and
estradiol. Endometrial carcinomas that express ERa tend to be less
aggressive than tumours that have no ERa expression [40]. In the
studies of miRNA expression in endometrial carcinomas, the up-
regulation of the miR-200 family may be influenced by estradiol
and ERa and this possibility deserves further study. It may be that
the less aggressive nature of ERa-positive endometrial carcinomas
relates to the up-regulation of the miR-200 family, which, in turn,
maintains an epithelial phenotype and resists the EMT transition.
In this study, there was no significant difference in miR-200 family
levels between lower grade 1 and 2 tumours compared to grade 3
tumours (data not shown); however, this study did not have a
sufficiently large sample size to see such a difference.
MicroRNAs are becoming important molecules in cancer
research; they have been implicated in tumorigenesis and have
been used both as biomarkers for cancer and as markers for
prognostication. Previous studies have shown that miRNAs are
Table 4. Summary of available studies detailing miRNA expression profiles in EEC compared to normal controls.
Study Increased Expression Decreased Expression
Tissues
(Fresh unless specified) Platform Used Statistics
Boren et al 2008 [22] let-7c miR-103 miR-106a
miR107 miR-181a miR-185
miR-210 miR-423
let 7i miR-152 miR-193
miR-221 miR-30c
Normal postmenopausal
endometrium (n=20)
Atypical hyperplasia
(n=4)
EEC (n=37)
Microarray Mann-Whitney,
p,0.02
Chung et al 2008 [23] miR-103 miR-106a miR-107
miR-10a miR-130b miR-141
miR-151 miR-155 miR-17-5p
miR-182 miR-183 miR-184
miR-191
miR-194 miR-200a
miR-200c miR-203
miR-205 miR-210 miR-215
miR-223 miR-23a* miR-25
miR-28 miR-301 miR-325 miR-
326 miR-330 miR-34a miR-95
Normal endometrium
(proliferative n=7,
secretory n=7,
postmenopausal n=8)
EEC (n=30)
RT-PCR T-test p,0.01,
FC.2 with a mean
difference of 100,
FDR=0.5%
Wu et al 2009 [24] miR-10a miR-141 miR-142-5p
miR-155 miR-182 miR-200a
miR-200b miR-200c miR-203
miR-205 miR-210 miR-31
miR-363 miR-429 miR-432
miR-449 miR-96
miR-133b miR-193a
miR-193b miR-204
miR-368
miR-99b
EEC with normal
adjacent endometrium
(n=10)
Microarray SAM with FDR
0% and FC.3.0
Ratner et al 2010 [25] miR-182 miR-183 miR-200a
miR-205 miR-34a miR-572
miR-622 miR-650
miR-411 miR-487b EEC (11 fresh and 46 FFPE)
and 5 ‘‘benign endometrial
tissues’’
Microarray T-test p,0.05
Cohn et al 2010 [26] miR-146 miR-181c miR-183
miR-19b miR-200c miR-205
miR-223 miR-423 miR-425
miR-9
let-7a miR-32 miR-33b
miR-369 miR-409 miR-424
miR-431 miR-451 miR-496
miR-503 miR-516
Stage 1 EEC (121 FFPE) and
20 normal unmatched
endometrial samples (FFPE;
10 premenopausal and 10
postmenopausal)
Microarray Class prediction
method p,0.001
MicroRNAs which have similar expression changes among the studies are italicized and the miR-200 family miRNAs are bolded.
doi:10.1371/journal.pone.0022828.t004
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expression profile. The most striking similarity among studies of
miRNA expression in EEC is the up-regulation of the miR-200
family. While most tumours have shown a down-regulation of the
miR-200 family, the up-regulation observed in endometrial
carcinoma is shared with a few other tumours including
melanoma, ovarian carcinoma, and colorectal carcinoma. Efforts
to elucidate the role that miRNAs play in endometrial carcinoma
should focus on the miR-200 family as well as the other miRNAs
that are consistently dysregulated in the multiple studies of
endometrial carcinoma to date.
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